CN¥ 18.72
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Jiangsu gdk Biotechnology Co., Ltd. operates as a biotechnology firm specializing in the comprehensive research, development, manufacturing, and commercialization of human vaccines, alongside providing related services. Its current portfolio includes a quadrivalent split-virus influenza vaccine and a lyophilized human rabies vaccine. The company's pipeline is strategically focused on preventing major infectious diseases such as influenza, rabies, chickenpox, shingles, and pneumonia. This enterprise was established in 2008 and is headquartered in Taizhou, China.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Data is available to registered users only